{"id":9415,"date":"2026-03-13T16:27:08","date_gmt":"2026-03-13T16:27:08","guid":{"rendered":"https:\/\/stoxpo.com\/?p=9415"},"modified":"2026-03-13T16:27:08","modified_gmt":"2026-03-13T16:27:08","slug":"bioaffinity-technologies-stock-surges-120-as-cypath-lung-sales-accelerate","status":"publish","type":"post","link":"https:\/\/stoxpo.com\/index.php\/2026\/03\/13\/bioaffinity-technologies-stock-surges-120-as-cypath-lung-sales-accelerate\/","title":{"rendered":"bioAffinity Technologies Stock Surges 120% as CyPath Lung Sales Accelerate"},"content":{"rendered":"\n<h4 class=\"wp-block-heading\">Strong commercial adoption of lung cancer diagnostic test fuels investor enthusiasm<\/h4>\n\n\n\n<p class=\"wp-block-paragraph\">Shares of <strong>bioAffinity Technologies<\/strong> (BIAF) experienced a dramatic rally, soaring more than <strong>120%<\/strong> following news of strong sales growth for the company\u2019s flagship diagnostic product, <strong>CyPath Lung<\/strong>. The surge reflects growing investor confidence in the company\u2019s ability to expand adoption of its innovative lung cancer detection technology.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">CyPath Lung is designed as a <strong>noninvasive diagnostic test<\/strong> aimed at improving the early detection of lung cancer, particularly among individuals considered at high risk for the disease. Early detection remains one of the most critical challenges in lung cancer treatment, as the condition is often diagnosed at advanced stages when treatment options become more limited. bioAffinity\u2019s technology seeks to address that gap by providing clinicians with a tool that can help identify cancer earlier and potentially improve patient outcomes.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The recent sales momentum suggests increasing interest from healthcare providers and medical institutions. As adoption of CyPath Lung expands, the company appears to be gaining traction in the competitive diagnostics market. Investors responded quickly to the news, pushing the stock sharply higher as they reassessed the company\u2019s growth potential.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The strong performance also highlights the broader opportunity within the <strong>early cancer detection market<\/strong>, which continues to attract significant attention from investors and healthcare innovators. Technologies that can identify cancer at earlier stages are widely seen as a major advancement in preventive medicine and personalized healthcare.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">For bioAffinity Technologies, the surge in CyPath Lung sales may represent an important step toward broader commercialization and long-term revenue growth. If the company can continue expanding physician awareness and clinical adoption of its diagnostic platform, it could strengthen its position within the rapidly evolving biotechnology sector.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">While the recent stock rally reflects optimism, market participants will be watching closely to see whether the company can sustain this momentum. Continued sales growth, additional clinical validation, and expanded partnerships with healthcare providers could play key roles in determining bioAffinity\u2019s trajectory in the months ahead.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">You might like this article:<a href=\"https:\/\/stoxpo.com\/index.php\/2026\/03\/12\/investor-confidence-builds-around-coreweave-and-nebius-amid-ai-infrastructure-boom\/\"><mark style=\"background-color:rgba(0, 0, 0, 0)\" class=\"has-inline-color has-vivid-cyan-blue-color\">Investor Confidence Builds Around CoreWeave and Nebius Amid AI Infrastructure Boom<\/mark><\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Strong commercial adoption of lung cancer diagnostic test fuels investor enthusiasm Shares of bioAffinity Technologies (BIAF) experienced a dramatic rally, soaring more than 120% following news of strong sales growth for the company\u2019s flagship diagnostic product, CyPath Lung. The surge reflects growing investor confidence in the company\u2019s ability to expand adoption of its innovative lung [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":5518,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"jnews-multi-image_gallery":[],"jnews_single_post":[],"jnews_primary_category":[],"jnews_social_meta":[],"jnews_override_counter":[],"jnews_post_split":[],"footnotes":""},"categories":[308,359],"tags":[933,421,416,418,417],"coauthors":[454],"class_list":["post-9415","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-biotechnology","category-small-cap","tag-biaf","tag-growth","tag-movers","tag-news","tag-stock-market"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>bioAffinity Technologies Stock Surges 120% as CyPath Lung Sales Accelerate - Stoxpo<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/stoxpo.com\/index.php\/2026\/03\/13\/bioaffinity-technologies-stock-surges-120-as-cypath-lung-sales-accelerate\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"bioAffinity Technologies Stock Surges 120% as CyPath Lung Sales Accelerate - Stoxpo\" \/>\n<meta property=\"og:description\" content=\"Strong commercial adoption of lung cancer diagnostic test fuels investor enthusiasm Shares of bioAffinity Technologies (BIAF) experienced a dramatic rally, soaring more than 120% following news of strong sales growth for the company\u2019s flagship diagnostic product, CyPath Lung. The surge reflects growing investor confidence in the company\u2019s ability to expand adoption of its innovative lung [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/stoxpo.com\/index.php\/2026\/03\/13\/bioaffinity-technologies-stock-surges-120-as-cypath-lung-sales-accelerate\/\" \/>\n<meta property=\"og:site_name\" content=\"Stoxpo\" \/>\n<meta property=\"article:published_time\" content=\"2026-03-13T16:27:08+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/stoxpo.com\/wp-content\/uploads\/2024\/10\/pexels-edward-jenner-4031323-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1707\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Luca Blaumann\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Luca Blaumann\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2026\\\/03\\\/13\\\/bioaffinity-technologies-stock-surges-120-as-cypath-lung-sales-accelerate\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2026\\\/03\\\/13\\\/bioaffinity-technologies-stock-surges-120-as-cypath-lung-sales-accelerate\\\/\"},\"author\":{\"name\":\"Luca Blaumann\",\"@id\":\"https:\\\/\\\/stoxpo.com\\\/#\\\/schema\\\/person\\\/031a96817fc4447b1046e0a10baad806\"},\"headline\":\"bioAffinity Technologies Stock Surges 120% as CyPath Lung Sales Accelerate\",\"datePublished\":\"2026-03-13T16:27:08+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2026\\\/03\\\/13\\\/bioaffinity-technologies-stock-surges-120-as-cypath-lung-sales-accelerate\\\/\"},\"wordCount\":355,\"publisher\":{\"@id\":\"https:\\\/\\\/stoxpo.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2026\\\/03\\\/13\\\/bioaffinity-technologies-stock-surges-120-as-cypath-lung-sales-accelerate\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/stoxpo.com\\\/wp-content\\\/uploads\\\/2024\\\/10\\\/pexels-edward-jenner-4031323-scaled.jpg\",\"keywords\":[\"BIAF\",\"Growth\",\"Movers\",\"News\",\"Stock Market\"],\"articleSection\":[\"Biotechnology\",\"Small-Cap\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2026\\\/03\\\/13\\\/bioaffinity-technologies-stock-surges-120-as-cypath-lung-sales-accelerate\\\/\",\"url\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2026\\\/03\\\/13\\\/bioaffinity-technologies-stock-surges-120-as-cypath-lung-sales-accelerate\\\/\",\"name\":\"bioAffinity Technologies Stock Surges 120% as CyPath Lung Sales Accelerate - Stoxpo\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/stoxpo.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2026\\\/03\\\/13\\\/bioaffinity-technologies-stock-surges-120-as-cypath-lung-sales-accelerate\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2026\\\/03\\\/13\\\/bioaffinity-technologies-stock-surges-120-as-cypath-lung-sales-accelerate\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/stoxpo.com\\\/wp-content\\\/uploads\\\/2024\\\/10\\\/pexels-edward-jenner-4031323-scaled.jpg\",\"datePublished\":\"2026-03-13T16:27:08+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2026\\\/03\\\/13\\\/bioaffinity-technologies-stock-surges-120-as-cypath-lung-sales-accelerate\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2026\\\/03\\\/13\\\/bioaffinity-technologies-stock-surges-120-as-cypath-lung-sales-accelerate\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2026\\\/03\\\/13\\\/bioaffinity-technologies-stock-surges-120-as-cypath-lung-sales-accelerate\\\/#primaryimage\",\"url\":\"https:\\\/\\\/stoxpo.com\\\/wp-content\\\/uploads\\\/2024\\\/10\\\/pexels-edward-jenner-4031323-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/stoxpo.com\\\/wp-content\\\/uploads\\\/2024\\\/10\\\/pexels-edward-jenner-4031323-scaled.jpg\",\"width\":2560,\"height\":1707},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2026\\\/03\\\/13\\\/bioaffinity-technologies-stock-surges-120-as-cypath-lung-sales-accelerate\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/stoxpo.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"bioAffinity Technologies Stock Surges 120% as CyPath Lung Sales Accelerate\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/stoxpo.com\\\/#website\",\"url\":\"https:\\\/\\\/stoxpo.com\\\/\",\"name\":\"Stoxpo\",\"description\":\"Stock Market &amp; Financial News\",\"publisher\":{\"@id\":\"https:\\\/\\\/stoxpo.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/stoxpo.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/stoxpo.com\\\/#organization\",\"name\":\"Stoxpo\",\"url\":\"https:\\\/\\\/stoxpo.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/stoxpo.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/stoxpo.com\\\/wp-content\\\/uploads\\\/2024\\\/02\\\/4q4p91-LogoMakr.png\",\"contentUrl\":\"https:\\\/\\\/stoxpo.com\\\/wp-content\\\/uploads\\\/2024\\\/02\\\/4q4p91-LogoMakr.png\",\"width\":250,\"height\":250,\"caption\":\"Stoxpo\"},\"image\":{\"@id\":\"https:\\\/\\\/stoxpo.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/stoxpo.com\\\/#\\\/schema\\\/person\\\/031a96817fc4447b1046e0a10baad806\",\"name\":\"Luca Blaumann\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/b7bbde6ef0582da5f93c9ff12262ea37de640f314250f9e3cfaeb37e258a563a?s=96&d=mm&r=g90dbb3a40c7379bca26d2b3dc92b368b\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/b7bbde6ef0582da5f93c9ff12262ea37de640f314250f9e3cfaeb37e258a563a?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/b7bbde6ef0582da5f93c9ff12262ea37de640f314250f9e3cfaeb37e258a563a?s=96&d=mm&r=g\",\"caption\":\"Luca Blaumann\"},\"description\":\"Luca is a proficient stock market reporter with a passion for dissecting complex market dynamics and uncovering transformative industry developments. With years of experience in leading editorial teams and overseeing coverage of the stock market and publicly traded companies, Luca has honed the ability to translate finance jargon into easily digestible articles. For tips and inquiries, reach out to Luca at tips@stoxpo.com.\",\"url\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/author\\\/luca-blaumann\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"bioAffinity Technologies Stock Surges 120% as CyPath Lung Sales Accelerate - Stoxpo","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/stoxpo.com\/index.php\/2026\/03\/13\/bioaffinity-technologies-stock-surges-120-as-cypath-lung-sales-accelerate\/","og_locale":"en_US","og_type":"article","og_title":"bioAffinity Technologies Stock Surges 120% as CyPath Lung Sales Accelerate - Stoxpo","og_description":"Strong commercial adoption of lung cancer diagnostic test fuels investor enthusiasm Shares of bioAffinity Technologies (BIAF) experienced a dramatic rally, soaring more than 120% following news of strong sales growth for the company\u2019s flagship diagnostic product, CyPath Lung. The surge reflects growing investor confidence in the company\u2019s ability to expand adoption of its innovative lung [&hellip;]","og_url":"https:\/\/stoxpo.com\/index.php\/2026\/03\/13\/bioaffinity-technologies-stock-surges-120-as-cypath-lung-sales-accelerate\/","og_site_name":"Stoxpo","article_published_time":"2026-03-13T16:27:08+00:00","og_image":[{"width":2560,"height":1707,"url":"https:\/\/stoxpo.com\/wp-content\/uploads\/2024\/10\/pexels-edward-jenner-4031323-scaled.jpg","type":"image\/jpeg"}],"author":"Luca Blaumann","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Luca Blaumann","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/stoxpo.com\/index.php\/2026\/03\/13\/bioaffinity-technologies-stock-surges-120-as-cypath-lung-sales-accelerate\/#article","isPartOf":{"@id":"https:\/\/stoxpo.com\/index.php\/2026\/03\/13\/bioaffinity-technologies-stock-surges-120-as-cypath-lung-sales-accelerate\/"},"author":{"name":"Luca Blaumann","@id":"https:\/\/stoxpo.com\/#\/schema\/person\/031a96817fc4447b1046e0a10baad806"},"headline":"bioAffinity Technologies Stock Surges 120% as CyPath Lung Sales Accelerate","datePublished":"2026-03-13T16:27:08+00:00","mainEntityOfPage":{"@id":"https:\/\/stoxpo.com\/index.php\/2026\/03\/13\/bioaffinity-technologies-stock-surges-120-as-cypath-lung-sales-accelerate\/"},"wordCount":355,"publisher":{"@id":"https:\/\/stoxpo.com\/#organization"},"image":{"@id":"https:\/\/stoxpo.com\/index.php\/2026\/03\/13\/bioaffinity-technologies-stock-surges-120-as-cypath-lung-sales-accelerate\/#primaryimage"},"thumbnailUrl":"https:\/\/stoxpo.com\/wp-content\/uploads\/2024\/10\/pexels-edward-jenner-4031323-scaled.jpg","keywords":["BIAF","Growth","Movers","News","Stock Market"],"articleSection":["Biotechnology","Small-Cap"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/stoxpo.com\/index.php\/2026\/03\/13\/bioaffinity-technologies-stock-surges-120-as-cypath-lung-sales-accelerate\/","url":"https:\/\/stoxpo.com\/index.php\/2026\/03\/13\/bioaffinity-technologies-stock-surges-120-as-cypath-lung-sales-accelerate\/","name":"bioAffinity Technologies Stock Surges 120% as CyPath Lung Sales Accelerate - Stoxpo","isPartOf":{"@id":"https:\/\/stoxpo.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/stoxpo.com\/index.php\/2026\/03\/13\/bioaffinity-technologies-stock-surges-120-as-cypath-lung-sales-accelerate\/#primaryimage"},"image":{"@id":"https:\/\/stoxpo.com\/index.php\/2026\/03\/13\/bioaffinity-technologies-stock-surges-120-as-cypath-lung-sales-accelerate\/#primaryimage"},"thumbnailUrl":"https:\/\/stoxpo.com\/wp-content\/uploads\/2024\/10\/pexels-edward-jenner-4031323-scaled.jpg","datePublished":"2026-03-13T16:27:08+00:00","breadcrumb":{"@id":"https:\/\/stoxpo.com\/index.php\/2026\/03\/13\/bioaffinity-technologies-stock-surges-120-as-cypath-lung-sales-accelerate\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/stoxpo.com\/index.php\/2026\/03\/13\/bioaffinity-technologies-stock-surges-120-as-cypath-lung-sales-accelerate\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/stoxpo.com\/index.php\/2026\/03\/13\/bioaffinity-technologies-stock-surges-120-as-cypath-lung-sales-accelerate\/#primaryimage","url":"https:\/\/stoxpo.com\/wp-content\/uploads\/2024\/10\/pexels-edward-jenner-4031323-scaled.jpg","contentUrl":"https:\/\/stoxpo.com\/wp-content\/uploads\/2024\/10\/pexels-edward-jenner-4031323-scaled.jpg","width":2560,"height":1707},{"@type":"BreadcrumbList","@id":"https:\/\/stoxpo.com\/index.php\/2026\/03\/13\/bioaffinity-technologies-stock-surges-120-as-cypath-lung-sales-accelerate\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/stoxpo.com\/"},{"@type":"ListItem","position":2,"name":"bioAffinity Technologies Stock Surges 120% as CyPath Lung Sales Accelerate"}]},{"@type":"WebSite","@id":"https:\/\/stoxpo.com\/#website","url":"https:\/\/stoxpo.com\/","name":"Stoxpo","description":"Stock Market &amp; Financial News","publisher":{"@id":"https:\/\/stoxpo.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/stoxpo.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/stoxpo.com\/#organization","name":"Stoxpo","url":"https:\/\/stoxpo.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/stoxpo.com\/#\/schema\/logo\/image\/","url":"https:\/\/stoxpo.com\/wp-content\/uploads\/2024\/02\/4q4p91-LogoMakr.png","contentUrl":"https:\/\/stoxpo.com\/wp-content\/uploads\/2024\/02\/4q4p91-LogoMakr.png","width":250,"height":250,"caption":"Stoxpo"},"image":{"@id":"https:\/\/stoxpo.com\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/stoxpo.com\/#\/schema\/person\/031a96817fc4447b1046e0a10baad806","name":"Luca Blaumann","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/b7bbde6ef0582da5f93c9ff12262ea37de640f314250f9e3cfaeb37e258a563a?s=96&d=mm&r=g90dbb3a40c7379bca26d2b3dc92b368b","url":"https:\/\/secure.gravatar.com\/avatar\/b7bbde6ef0582da5f93c9ff12262ea37de640f314250f9e3cfaeb37e258a563a?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/b7bbde6ef0582da5f93c9ff12262ea37de640f314250f9e3cfaeb37e258a563a?s=96&d=mm&r=g","caption":"Luca Blaumann"},"description":"Luca is a proficient stock market reporter with a passion for dissecting complex market dynamics and uncovering transformative industry developments. With years of experience in leading editorial teams and overseeing coverage of the stock market and publicly traded companies, Luca has honed the ability to translate finance jargon into easily digestible articles. For tips and inquiries, reach out to Luca at tips@stoxpo.com.","url":"https:\/\/stoxpo.com\/index.php\/author\/luca-blaumann\/"}]}},"_links":{"self":[{"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/posts\/9415","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/comments?post=9415"}],"version-history":[{"count":1,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/posts\/9415\/revisions"}],"predecessor-version":[{"id":9416,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/posts\/9415\/revisions\/9416"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/media\/5518"}],"wp:attachment":[{"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/media?parent=9415"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/categories?post=9415"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/tags?post=9415"},{"taxonomy":"author","embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/coauthors?post=9415"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}